Trustworthy and ethical AI-enabled cardiovascular care: a rapid review

BACKGROUND

Artificial intelligence (AI) is increasingly used for prevention, diagnosis, monitoring, and treatment of cardiovascular diseases. Despite the potential for AI to improve care, ethical concerns and mistrust in AI-enabled healthcare exist among the public and medical community. Given the rapid and transformative recent growth of AI in cardiovascular care, to inform practice guidelines and regulatory policies that facilitate ethical and trustworthy use of AI in medicine, we conducted a literature review to identify key ethical and trust barriers and facilitators from patients' and healthcare providers' perspectives when using AI in cardiovascular care.

METHODS

In this rapid literature review, we searched six bibliographic databases to identify publications discussing transparency, trust, or ethical concerns (outcomes of interest) associated with AI-based medical devices (interventions of interest) in the context of cardiovascular care from patients', caregivers', or healthcare providers' perspectives. The search was completed on May 24, 2022 and was not limited by date or study design.

RESULTS

After reviewing 7,925 papers from six databases and 3,603 papers identified through citation chasing, 145 articles were included. Key ethical concerns included privacy, security, or confidentiality issues (n = 59, 40.7%); risk of healthcare inequity or disparity (n = 36, 24.8%); risk of patient harm (n = 24, 16.6%); accountability and responsibility concerns (n = 19, 13.1%); problematic informed consent and potential loss of patient autonomy (n = 17, 11.7%); and issues related to data ownership (n = 11, 7.6%). Major trust barriers included data privacy and security concerns, potential risk of patient harm, perceived lack of transparency about AI-enabled medical devices, concerns about AI replacing human aspects of care, concerns about prioritizing profits over patients' interests, and lack of robust evidence related to the accuracy and limitations of AI-based medical devices. Ethical and trust facilitators included ensuring data privacy and data validation, conducting clinical trials in diverse cohorts, providing appropriate training and resources to patients and healthcare providers and improving their engagement in different phases of AI implementation, and establishing further regulatory oversights.

CONCLUSION

This review revealed key ethical concerns and barriers and facilitators of trust in AI-enabled medical devices from patients' and healthcare providers' perspectives. Successful integration of AI into cardiovascular care necessitates implementation of mitigation strategies. These strategies should focus on enhanced regulatory oversight on the use of patient data and promoting transparency around the use of AI in patient care.

The Saudi Community View of the Use of Artificial Intelligence in Health Care

OBJECTIVES

Artificial intelligence (AI) holds the promise to revolutionize the field of medicine and enhance the well-being of countless patients. Its capabilities span various areas, including disease prevention, accurate diagnosis, and the development of innovative treatments. Moreover, AI has the potential to streamline health-care delivery and lower expenses. The community should be aware of the potential applications of AI in health care, so that they can advocate for its development and adoption. Hence, the objective of this study is to assess the community's perspectives regarding the utilization of AI in health care.

METHODS

A cross-sectional, questionnaire-based study was conducted in Saudi Arabia during the period of June to October 2023. The questionnaire was distributed to people on various social media platforms using a convenience sampling method. The collected data were analyzed using Statistical Package for the Social Sciences.

RESULTS

The study included 771 individuals, with 42.5% having a positive outlook on the use of AI in health care, 31.8% having a neutral view, and 7.5% having a negative view. The only factor associated with a positive opinion was regional differences (P = 0.006). Moreover, participants who used medical apps or programs (P = 0.026), wearables (P = 0.027), felt more confident in using technology (P < 0.001), enjoyed using technology (P < 0.001), found it easier to familiarize themselves with new devices or programs (P < 0.001), and had more knowledge about AI (P < 0.001) had more positive opinions regarding the use of AI in health care.

CONCLUSIONS

The study found that most Saudis, especially those who were familiar with the use of technology, support the use of AI in health care, with a positive or neutral view. Yet, targeted campaigns in certain regions are needed to educate the entire community about AI's potential benefits.

A New Era of Dental Care: Harnessing Artificial Intelligence for Better Diagnosis and Treatment

The integration of artificial intelligence (AI) into dental care holds the promise of revolutionizing the field by enhancing the accuracy of dental diagnosis and treatment. This paper explores the impact of AI in dental care, with a focus on its applications in diagnosis, treatment planning, and patient engagement. AI-driven dental imaging and radiography, computer-aided detection and diagnosis of dental conditions, and early disease detection and prevention are discussed in detail. Moreover, the paper delves into how AI assists in personalized treatment planning and provides predictive analytics for dental care. Ethical and privacy considerations, including data security, fairness, and regulatory aspects, are addressed, highlighting the need for a responsible and transparent approach to AI implementation. Finally, the paper underscores the potential for a collaborative partnership between AI and dental professionals to offer the best possible care to patients, making dental care more efficient, patient-centric, and effective. The advent of AI in dentistry presents a remarkable opportunity to improve oral health outcomes, benefiting both patients and the healthcare community.

Implementation of Machine Learning Applications in Health Care Organizations: Protocol for a Systematic Review of Empirical Studies

BACKGROUND

An increasing interest in machine learning (ML) has been observed among scholars and health care professionals. However, while ML-based applications have been shown to be effective and have the potential to change the delivery of patient care, their implementation in health care organizations is complex. There are several challenges that currently hamper the uptake of ML in daily practice, and there is currently limited knowledge on how these challenges have been addressed in empirical studies on implemented ML-based applications.

OBJECTIVE

The aim of this systematic literature review is twofold: (1) to map the ML-based applications implemented in health care organizations, with a focus on investigating the organizational dimensions that are relevant in the implementation process; and (2) to analyze the processes and strategies adopted to foster a successful uptake of ML.

METHODS

We developed this protocol following the PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) guidelines. The search was conducted on 3 databases (PubMed, Scopus, and Web of Science), considering a 10-year time frame (2013-2023). The search strategy was built around 4 blocks of keywords (artificial intelligence, implementation, health care, and study type). Based on the detailed inclusion criteria defined, only empirical studies documenting the implementation of ML-based applications used by health care professionals in clinical settings will be considered. The study protocol was registered in PROSPERO (International Prospective Register of Systematic Reviews).

RESULTS

The review is ongoing and is expected to be completed by September 2023. Data analysis is currently underway, and the first results are expected to be submitted for publication in November 2023. The study was funded by the European Union within the Multilayered Urban Sustainability Action (MUSA) project.

CONCLUSIONS

ML-based applications involving clinical decision support and automation of clinical tasks present unique traits that add several layers of complexity compared with earlier health technologies. Our review aims at contributing to the existing literature by investigating the implementation of ML from an organizational perspective and by systematizing a conspicuous amount of information on factors influencing implementation.

INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)

DERR1-10.2196/47971.

FDA-approved machine learning algorithms in neuroradiology: A systematic review of the current evidence for approval

Over the past decade, machine learning (ML) and artificial intelligence (AI) have become increasingly prevalent in the medical field. In the United States, the Food and Drug Administration (FDA) is responsible for regulating AI algorithms as "medical devices" to ensure patient safety. However, recent work has shown that the FDA approval process may be deficient. In this study, we evaluate the evidence supporting FDA-approved neuroalgorithms, the subset of machine learning algorithms with applications in the central nervous system (CNS), through a systematic review of the primary literature. Articles covering the 53 FDA-approved algorithms with applications in the CNS published in PubMed, EMBASE, Google Scholar and Scopus between database inception and January 25, 2022 were queried. Initial searches identified 1505 studies, of which 92 articles met the criteria for extraction and inclusion. Studies were identified for 26 of the 53 neuroalgorithms, of which 10 algorithms had only a single peer-reviewed publication. Performance metrics were available for 15 algorithms, external validation studies were available for 24 algorithms, and studies exploring the use of algorithms in clinical practice were available for 7 algorithms. Papers studying the clinical utility of these algorithms focused on three domains: workflow efficiency, cost savings, and clinical outcomes. Our analysis suggests that there is a meaningful gap between the FDA approval of machine learning algorithms and their clinical utilization. There appears to be room for process improvement by implementation of the following recommendations: the provision of compelling evidence that algorithms perform as intended, mandating minimum sample sizes, reporting of a predefined set of performance metrics for all algorithms and clinical application of algorithms prior to widespread use. This work will serve as a baseline for future research into the ideal regulatory framework for AI applications worldwide.

Artificial Intelligence in Medicine and Dentistry

INTRODUCTION

Artificial intelligence has been applied in various fields throughout history, but its integration into daily life is more recent. The first applications of AI were primarily in academia and government research institutions, but as technology has advanced, AI has also been applied in industry, commerce, medicine and dentistry.

OBJECTIVE

Considering that the possibilities of applying artificial intelligence are developing rapidly and that this field is one of the areas with the greatest increase in the number of newly published articles, the aim of this paper was to provide an overview of the literature and to give an insight into the possibilities of applying artificial intelligence in medicine and dentistry. In addition, the aim was to discuss its advantages and disadvantages.

CONCLUSION

The possibilities of applying artificial intelligence to medicine and dentistry are just being discovered. Artificial intelligence will greatly contribute to developments in medicine and dentistry, as it is a tool that enables development and progress, especially in terms of personalized healthcare that will lead to much better treatment outcomes.

Women’s perceptions and attitudes to the use of AI in breast cancer screening: a survey in a cancer referral centre

Objective:

Although breast cancer screening can benefit from Artificial Intelligence (AI), it is still unknown whether, to which extent or under which conditions, the use of AI is going to be accepted by the general population. The aim of our study is to evaluate what the females who are eligible for breast cancer screening know about AI and how they perceive such innovation.

Methods:

We used a prospective survey consisting of a 11-multiple-choice questionnaire evaluating statistical associations with Chi-Square-test or Fisher-exact-test. Multinomial-logistic-regression was performed on items with more than two response categories. Odds ratio (OR) with 95% CI were computed to estimate the probability of a specific response according to patient’s characteristics.

Results:

In the 800 analysed questionnaires, 51% of respondents confirmed to have knowledge of AI. Of these, 88% expressed a positive opinion about its use in medicine. Non-Italian respondents were associated with the belief of having a deep awareness about AI more often than Italian respondents (OR = 1.91;95% CI[1.10–3.33]). Higher education level was associated with better opinions on the use of AI in medicine (OR = 4.69;95% CI[1.36–16.12]). According to 94% of respondents, the radiologists should always produce their own report on mammograms, whilst 77% agreed that AI should be used as a second reader. Most respondents (52%) considered that both the software developer and the radiologist should be held accountable for AI errors.

Conclusions:

Most of the females undergoing screening in our Institute approve the introduction of AI, although only as a support to radiologist, and not in substitution thereof. Yet, accountability in case of AI errors is still unsolved. advances in knowledge: This survey may be considered as a pilot-study for the development of large-scale studies to understand females’s demands and concerns about AI applications in breast cancer screening.

The Good, the Bad, and the Invisible with Its Opportunity Costs: Introduction to the ‘J’ Special Issue on “the Impact of Artificial Intelligence on Law”

Scholars and institutions have been increasingly debating the moral and legal challenges of AI, together with the models of governance that should strike the balance between the opportunities and threats brought forth by AI, its ‘good’ and ‘bad’ facets. There are more than a hundred declarations on the ethics of AI and recent proposals for AI regulation, such as the European Commission’s AI Act, have further multiplied the debate. Still, a normative challenge of AI is mostly overlooked, and regards the underuse, rather than the misuse or overuse, of AI from a legal viewpoint. From health care to environmental protection, from agriculture to transportation, there are many instances of how the whole set of benefits and promises of AI can be missed or exploited far below its full potential, and for the wrong reasons: business disincentives and greed among data keepers, bureaucracy and professional reluctance, or public distrust in the era of no-vax conspiracies theories. The opportunity costs that follow this technological underuse is almost terra incognita due to the ‘invisibility’ of the phenomenon, which includes the ‘shadow prices’ of economy. This introduction provides metrics for such assessment and relates this work to the development of new standards for the field. We must quantify how much it costs not to use AI systems for the wrong reasons.